The mandatory tests for every patient with advanced NSCLC are EGFR and BRAF mutations, ALK and ROS1 rearrangements [17, 24, 40], and PD-L1 expression [17, 40]. This evidence concerns the gene ALK and non-small cell lung carcinoma.